Skip to main content

Comparative Effectiveness from Real World Data

Pioneers and leaders in comparative effectiveness and pharma health economics and outcomes research and real world data will debate the various challenges posed by the evolving need to extract evidence from clinical trial and real world data.

Photo of Marc Berger, M.D.

Marc Berger, M.D.

Pfizer

Marc L. Berger, M.D. is Vice President, Real World Data and Analytics at Pfizer. Prior to joining Pfizer in September 2012, he was Executive Vice President and Senior Scientist, in the life sciences group of OptumInsight (formerly known as Ingenix). A native of New York, he has held senior positions in the pharmaceutical industry including Vice President, Outcomes Research and Management at Merck & Co., Inc. from 2002 – 2007, and Vice President, Global Health Outcomes, at Eli Lilly and Company from 2007 – 2011. He obtained an M.D. degree from Johns Hopkins University School of Medicine and has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. He has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Center for Medicare & Medicaid Services (CMS), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the steering committee for the Agency for Health Care Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs), the board of the Health Industry Forum of the Heller School for Social Policy and Management at Brandeis University and the Editorial Advisory Board of Value in Health. He recently served as co-chair of the ISPOR Taskforce on Prospective Observational Studies for Comparative Effectiveness Research. Currently, he is a member of the editorial advisory board of the Journal of Comparative Effectiveness Research, the advisory council for North America (ACNA) of the Drug Information Association (DIA) and the Green Park Collaborative on HTA/Payer Methods Guidance coordinated by the Center for Medical Technology Policy (CMTP). He also currently serves as chair of the AMCP/NPC/ISPOR Comparative Effectiveness Collaborative Initiative Taskforce for the Interpreting Prospective Observational Studies for Health Care Decisions. Marc has written or co-written more than 100 peer-reviewed articles, book chapters, and other publications on a range of topics including health services research, outcomes research, health economics, and health policy. He co-edited “Health Care, Cost, Quality, and Outcomes – ISPOR Book of Terms” which was published in 2003 and was subsequently translated into nine languages.

Photo of Robert Epstein, M.D.

Robert Epstein, M.D.

Dr. Robert Epstein is a physician epidemiologist with an interest in bringing true innovation and hope to those in need of novel healthcare solutions. He has worked for 30 years in the public and private healthcare sectors and recently left a 15 year post as Chief Medical and Chief R&D Officer for Medco, where he managed a global department of over 2000 researchers in 33 offices. He is a frequent speaker at conferences in the US and abroad, and is often interviewed in the media , appearing on CNN, CNBC, or daily news programs, He has published more than 75 research papers in the peer-reviewed medical literature, and is currently tracking and engaging with developers of hundreds of new technologies. He serves on the Boards of Directors of Illumina (ILMN), Aveo (AVEO), and Proteus Digital Health. He can be reached at repstein@epsteinhealth.com.

Photo of Usman Iqbal

Usman Iqbal

Sanofi

Dr Usman Iqbal MD, MPH, MBA, is the head of Oncology Global Evidence &, Value Development at Sanofi, where he is responsible for developing product value for Sanofi’s oncology/hematology portfolio through strategic development, execution and translation of evidence based research throughout the lifecycle of the products. His health care experience spans clinical medicine, health policy and management, health economic &, outcomes research in both academia and biopharmaceutical industry, including Amgen and Boehringer Ingelheim. Dr Iqbal has broad based experience in building value and product differentiation across multiple therapeutic areas including oncology, respiratory, rheumatology, hepatology, and mental health. Prior to working in the industry, Dr Iqbal was at the Boston University Health Outcomes Technology Group as a senior research fellow and served as a research consultant for Veterans Affairs Pharmacy Benefit Management (VA-PBM), the Centers for Medicare &, Medicaid Services’ Health Outcomes Survey Initiative (CMS-HOS), the Agency for Healthcare Research and Quality (AHRQ), and the National Committee for Quality Assurance (NCQA). His research experience encompasses outcomes evaluation in large integrated health care systems and databases with a specific focus on comparative effectiveness, disease management, patients’ health related quality of life, and risk-adjustment methodologies. Dr Iqbal received his MD from Allama Iqbal Medical College, Lahore, Pakistan and Master of Public Health and Master of Business Administration from Boston University.

For exhibition and sponsorship opportunities at Strata Rx conference, contact Sharon Pierce at (203) 304-9476 or spierce@oreilly.com

For information on trade opportunities with O'Reilly conferences email mediapartners
@oreilly.com

View a complete list of Strata Rx 2013 contacts